Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able to gain favorable insurance coverage despite questions about how the Trump ...

Gilead Sciences’ stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

She expressed optimism for ultimately widespread coverage of the drug. Gilead will cover up to $7,200 annually in out-of-pocket costs for insured people receiving Yeztugo.

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

The FDA uses data submitted by a drug's maker when it's considering approval. Gilead submitted a study published in the New England Journal of Medicine that showed the drug shortened the course of ...

The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

Arcus says Gilead-partnered cancer drug won FDA orphan status Jul. 10, 2025 10:24 AM ET Arcus Biosciences, Inc. (RCUS) Stock, GILD Stock By: Nilanjana Basu, SA News Editor 1 Comment Play (1min) ...

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. The regulatory body approved lenacapavir, under the ...